Active, Recruiting

This is an upcoming trial to study the effect of a botensilimab and balstilimab regimen in CRC patients with MRD after completing definitive standard-of-care therapy.

This is a Phase II trial to study whether the combination of botensilimab and balstilimab, followed by balstilimab alone, is an effective treatment for CRC patients with MRD after standard treatment with surgery and chemotherapy or total neoadjuvant therapy.

This is a study to measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy.

This is a study to assess the effects of the drugs Regorafenib and Lorigerlimab on circulating tumor DNA (ctDNA) in patients with CRC and who have radiographic occult minimal residual disease (MRD) after completing standard-of-care therapy.

This is a study to assess adverse events and change in disease activity in adult participants receiving intravenously infused Telisotuzumab Adizutecan alone or with standard of care in participants with post adjuvant circulating tumor DNA positive colorectal cancer and no radiographic evidence of disease.

This is a Phase II trial to study control of MRD with a combination of Fruquitinib (VEGFR inhibitor) and Tislelizumab (PD-1 inhibitor) in CRC patients after adjuvant chemotherapy.

This is an observational study, monitoring participants while receiving standard-of-care biomarker-directed therapy with the goal to learn about the effects of these therapies on ctDNA in participants with minimal residual colorectal cancer.

This is a Phase Ib, prospective, single arm, non-randomized, open-label clinical trial determining the efficacy of adjuvant trifluridine and tipiracil (TAS-102) in combination with irinotecan in patients with ctDNA positive colon adenocarcinoma.

This is a study designed to evaluate varying doses of TROP2-CAR-NK cells combined with cetuximab and their ability to clear ctDNA in patients with minimal residual colorectal cancer.

This is a Phase II trial studying atezolizumab and bevacizumab in ctDNA positive colorectal cancer patients with no evidence of cancer on imaging after completing standard therapies.